An integrated clinical risk scoring and machine learning framework for risk stratification of hepatocellular carcinoma: Development and real-world clinical validation

Introduction: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality, highlighting the need for more accurate risk stratification approaches. Objective: To develop and validate an integrated clinical risk scoring (CRS) and machine learning (ML) system to accurately identify HCC, overcoming the limitations of traditional alpha-fetoprotein (AFP) screening, especially in AFP-negative individuals. Methods: A retrospective cross-sectional diagnostic study utilized data from two institutions (development cohort n = 5,000; external validation cohort n = 443) with 12 routine clinical variables. Multivariable logistic regression was used to construct the CRS, and ensemble ML models were developed. Performance was assessed via area under the receiver operating characteristic curve (AUC), quantitative calibration measures, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). We applied development-trained models directly to the independent cohort for strict external validation. Results: Hepatitis C, diabetes and hepatitis B were identified as the strongest independent risk factors for HCC. In the development cohort, the CatBoost model demonstrated the best overall discriminatory ability (AUC = 0.9773), significantly outperforming the single AFP indicator (0.6377) and CRS (0.9385); notably, in the independent validation cohort, CRS demonstrated superior stability in terms of AUC (0.9849) and risk reclassification ability (NRI/IDI), performing slightly better than CatBoost (AUC = 0.9816). DCA, NRI, and IDI confirmed significant incremental clinical net benefit and risk reclassification over AFP-only screening (p < 0.001). Conclusion: This integrated HCC risk stratification system effectively overcomes traditional AFP screening limitations, particularly in AFP-negative populations. The observed bias-variance trade-off supports a tiered deployment strategy: CRS for robust screening in resource-limited settings, and ML for precision assessment in well-resourced centers.

Authors

Institutions

Publication Details

Journal
Eurasian Journal of Medicine and Oncology
Published
2026-11-16
DOI
https://doi.org/10.36922/ejmo026310393
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

An integrated clinical risk scoring and machine learning framework for risk stratification of hepatocellular carcinoma: Development and real-world clinical validation

刘丽红, Yingkang Lin, Zengbei Yuan, Yingying Luo et al.
5 links
Eurasian Journal of Medicine and Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

An integrated clinical risk scoring and machine learning framework for risk stratification of hepatocellular carcinoma: Development and real-world clinical validation

刘丽红, Yingkang Lin, Zengbei Yuan, Yingying Luo, Feiyang Pu, XiaoLei Huang, Rui Li, Zhihua Ni
article en

Abstract

Introduction: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality, highlighting the need for more accurate risk stratification approaches. Objective: To develop and validate an integrated clinical risk scoring (CRS) and machine learning (ML) system to accurately identify HCC, overcoming the limitations of traditional alpha-fetoprotein (AFP) screening, especially in AFP-negative individuals. Methods: A retrospective cross-sectional diagnostic study utilized data from two institutions (development cohort n = 5,000; external validation cohort n = 443) with 12 routine clinical variables. Multivariable logistic regression was used to construct the CRS, and ensemble ML models were developed. Performance was assessed via area under the receiver operating characteristic curve (AUC), quantitative calibration measures, decision curve analysis (DCA), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). We applied development-trained models directly to the independent cohort for strict external validation. Results: Hepatitis C, diabetes and hepatitis B were identified as the strongest independent risk factors for HCC. In the development cohort, the CatBoost model demonstrated the best overall discriminatory ability (AUC = 0.9773), significantly outperforming the single AFP indicator (0.6377) and CRS (0.9385); notably, in the independent validation cohort, CRS demonstrated superior stability in terms of AUC (0.9849) and risk reclassification ability (NRI/IDI), performing slightly better than CatBoost (AUC = 0.9816). DCA, NRI, and IDI confirmed significant incremental clinical net benefit and risk reclassification over AFP-only screening (p < 0.001). Conclusion: This integrated HCC risk stratification system effectively overcomes traditional AFP screening limitations, particularly in AFP-negative populations. The observed bias-variance trade-off supports a tiered deployment strategy: CRS for robust screening in resource-limited settings, and ML for precision assessment in well-resourced centers.

Eurasian Journal of Medicine and OncologyVol. 0(0)
Tongji University (CN), Fujian Medical University (CN), Guangdong Work Injury Rehabilitation Hospital (CN), Shanghai Pulmonary Hospital (CN), Shanghai Traditional Chinese Medicine Hospital (CN)
Good health and well-being
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon